發(fā)布時(shí)間：2018-06-19 21:36

  本文選題：非小細(xì)胞肺癌 + 組蛋白去乙酰化酶抑制劑��； 參考：《安徽醫(yī)科大學(xué)》2017年碩士論文

【摘要】：背景:表皮生長(zhǎng)因子受體(EGFR)酪氨酸激酶(tyrosine kinase,TK)抑制劑已被廣泛用于非小細(xì)胞肺癌(NSCLC)的治療,如厄洛替尼(Erlotinib)、吉非替尼(Gefitinib)等。EGFR-TKI在NSCLC的治療上取得了非常好的效果,特別是在具有EGFR基因突變的NSCLC,幾乎所有的患者在EGFR-TKI治療一年左右后都會(huì)發(fā)生耐藥現(xiàn)象,嚴(yán)重影響了EGFR-TKI的治療療效。研究表明,組蛋白去乙酰化酶(Histone Deacetylases inhibitor;HDACI)能夠抑制編碼如細(xì)胞周期抑制、分化、凋亡等相關(guān)因子的表達(dá)。此外HDACs還可以促進(jìn)與細(xì)胞侵襲和遷移和血管生成相關(guān)基因的表達(dá)。因此,HDACs在腫瘤的發(fā)生、發(fā)展中起重要作用。組蛋白去乙�；�(Histone Deacetylases;HDAC)抑制劑可以通過(guò)改變組蛋白及非組蛋白的乙�；�,從而影響基因轉(zhuǎn)錄。HDACIs在血液系統(tǒng)腫瘤,以及實(shí)體腫瘤的研究中,取得了比較理想的結(jié)果。同時(shí)研究表明,HDACIs在與放療以及其他抗腫瘤藥物的聯(lián)合作用中,顯示出較強(qiáng)的協(xié)同及增強(qiáng)作用。伏立諾他(SAHA)是一種廣譜的HDACIs,是第一個(gè)被FDA批準(zhǔn)用于T細(xì)胞淋巴瘤的治療。本研究通過(guò)體外誘導(dǎo)Erlotinib耐藥細(xì)胞株P(guān)C-9/ER,檢測(cè)其與親代Erlotinib敏感型細(xì)胞PC-9中PTEN表達(dá)的差異,結(jié)果表明,在PC-9/ER耐藥性的形成過(guò)程中,PTEN的表達(dá)受到抑制。提示PTEN在耐藥性的形成過(guò)程中起一定的作用。目的:檢測(cè)SAHA對(duì)PC-9/ER細(xì)胞的增殖、凋亡及其耐藥性的影響。方法:1.通過(guò)體外誘導(dǎo)耐藥的方法誘導(dǎo)PC-9(Erlotinib敏感型)細(xì)胞耐藥。開(kāi)始以10nmol/L Erlotinib培養(yǎng)PC-9細(xì)胞48h,棄去舊培養(yǎng)基以及無(wú)菌PBS清洗3遍,在無(wú)Erlotinib的環(huán)境下培養(yǎng)直至細(xì)胞生長(zhǎng)至80%~90%匯合度時(shí),逐漸升高的Erlotinib的濃度繼續(xù)培養(yǎng),直至PC-9細(xì)胞能正常生在在含1μmol/L的Erlotinib環(huán)境中。2.MTT法檢測(cè)PC-9,PC-9/ER對(duì)Erlotinib的敏感性。3.MTT法檢測(cè)SAHA單藥、Erlotinib單藥,以及無(wú)毒劑量的SAHA(1μmol/L)聯(lián)合Erlotinib處理后,PC-9/ER細(xì)胞株的增殖抑制情況。4.應(yīng)用FCM(Flow Cytometry,流式細(xì)胞術(shù)),Annexin V-FITC/PI雙染試劑盒檢測(cè)SAHA單藥、Erlotinib單藥,以及無(wú)毒劑量的SAHA(1μmol/L)聯(lián)合Erlotinib處理后,PC-9/ER細(xì)胞株的凋亡情況。5.應(yīng)用WB(Western Blot)法檢測(cè)PC-9與PC-9/ER細(xì)胞中PTEN表達(dá)情況。6.應(yīng)用WB(Western Blot)法檢測(cè)SAHA單藥、Erlotinib單藥,以及無(wú)毒劑量的SAHA(1μmol/L)聯(lián)合Erlotinib處理后,PC-9/ER細(xì)胞株中PTEN表達(dá)的差異。結(jié)果:1.體外誘導(dǎo)耐藥細(xì)胞株P(guān)C-9/ER對(duì)Erlotinib的敏感性明顯低于PC-9細(xì)胞。其耐藥倍數(shù)100,說(shuō)明耐Erlotinib細(xì)胞株的建立是成功的。2.SAHA單藥能抑制PC-9/ER的增殖,在無(wú)毒計(jì)量(1μmol/L)的SAHA與Erlotinib聯(lián)合作用于PC-9/ER細(xì)胞時(shí),能部分逆轉(zhuǎn)PC-9/ER的耐藥性,其逆轉(zhuǎn)倍數(shù)為3.01,相對(duì)逆轉(zhuǎn)率為66.8%。3.SAHA單藥即可促進(jìn)PC-9/ER細(xì)胞的凋亡,在無(wú)毒劑量(1μmol/L)與Erlotinib聯(lián)合,更能進(jìn)一步提高PC-9/ER細(xì)胞的凋亡率。4.WB(Western Blot)檢測(cè)PC-9/ER及PC-9細(xì)胞中PTEN的表達(dá)情況,結(jié)果顯示PC-9/ER中PTEN的表達(dá)明顯下調(diào)。5.WB檢測(cè)經(jīng)藥物處理后的PTEN表達(dá)情況,SAHA及SAHA+Erlotinib處理后48H后,PTEN的表達(dá)升高,與Erlotinib組及空白組相比,P0.05。結(jié)論:1.組蛋白去乙�；敢种芐AHA能夠部分改善Erlotinib耐藥細(xì)胞株P(guān)C-9/ER的耐藥性;2.SAHA能促進(jìn)PC-9/ER細(xì)胞的凋亡;3.PTEN的缺失在Erlotinib耐藥的產(chǎn)生中起一定的作用;4.SAHA能夠提高PTEN的表達(dá),促進(jìn)細(xì)胞凋亡,來(lái)改善Erlotinib的耐藥性。
[Abstract]:Background: epidermal growth factor receptor (EGFR) tyrosine kinase (tyrosine kinase, TK) inhibitors have been widely used for the treatment of non-small cell lung cancer (NSCLC), such as erlotinib (Erlotinib), and gefitinib (Gefitinib), and.EGFR-TKI in the treatment of NSCLC, especially in NSCLC with EGFR gene mutations, almost all of them The patients will have resistance to EGFR-TKI after a year or so, which seriously affects the therapeutic effect of EGFR-TKI. The study shows that histone deacetylase (Histone Deacetylases inhibitor; HDACI) can inhibit the expression of phase factors such as cell cycle inhibition, differentiation, apoptosis and so on. In addition, HDACs can also promote the invasion of cells with cell invasion. The expression of genes related to migration and angiogenesis. Therefore, HDACs plays an important role in the development of tumor. Histone deacetylase (Histone Deacetylases; HDAC) inhibitors can affect the level of histone and non histone acetylation, thus affecting the gene transcription of.HDACIs in the blood system tumor, as well as solid tumors. In the study, an ideal result was obtained. The study showed that HDACIs showed strong synergy and enhancement in combination with radiotherapy and other antitumor drugs. SAHA is a broad-spectrum HDACIs, the first FDA approved treatment for T cell lymphoma. This study induced Erlotinib in vitro. PC-9/ER, a drug resistant cell line, was used to detect the difference in the expression of PTEN in the Erlotinib sensitive cell PC-9 of the parents. The results showed that the expression of PTEN was inhibited during the formation of PC-9/ER resistance. It suggested that PTEN plays a role in the formation of drug resistance. Objective: to detect the effect of SAHA on the proliferation, apoptosis and drug resistance of PC-9/ER cells. Methods: 1. the drug resistance of PC-9 (Erlotinib sensitive) cells was induced by induction of drug resistance in vitro. PC-9 cell 48h was cultured with 10nmol/L Erlotinib, the old medium was abandoned and the aseptic PBS was cleaned 3 times, and the concentration of Erlotinib increased gradually when the cell grew to the 80%~90% confluence in the environment without Erlotinib. Until PC-9 cells can be normal in the Erlotinib environment containing 1 mu mol/L,.2.MTT method is used to detect PC-9, PC-9/ER to Erlotinib sensitivity.3.MTT method to detect SAHA single drug, Erlotinib single drug, and non toxic dose SAHA (1 micron mol/L). Annexin V-FITC/PI double staining kit was used to detect SAHA single drug, Erlotinib single drug, and non toxic dose SAHA (1 u mol/L) combined with Erlotinib treatment. The apoptosis of PC-9/ER cell lines was detected by WB (Western Blot) method. And the difference of PTEN expression in PC-9/ER cell lines after Erlotinib treatment with nontoxic dose of SAHA (1 mu mol/L). Results: 1. the sensitivity of PC-9/ER to Erlotinib in vitro was significantly lower than that of PC-9 cells. The multidrug resistance was 100, indicating that the establishment of a Erlotinib resistant cell line is a successful.2.SAHA single drug that inhibits PC-9/ER proliferation. When SAHA and Erlotinib are combined with Erlotinib in PC-9/ER cells, the drug resistance can partly reverse the resistance of PC-9/ER, and the reversal multiplier is 3.01. The relative reversal rate of 66.8%.3.SAHA single agent can promote the apoptosis of PC-9/ER cells, combined with Erlotinib (1 mu mol/L) and Erlotinib, and can further increase the.4.WB apoptosis rate of PC-9/ER cells (West) (West) (West) can further increase the.4.WB apoptosis rate of PC-9/ER cells (West) (West). (West),.4.WB (West) (West) can further increase the apoptotic rate of PC-9/ER cells (West) (West). (West),.4.WB (West) (West) can further enhance the apoptosis rate of PC-9/ER cells. The expression of PTEN in PC-9/ER and PC-9 cells was detected by ERN Blot. The results showed that the expression of PTEN in PC-9/ER obviously decreased the PTEN expression of.5.WB detected by drug treatment. After SAHA and SAHA+Erlotinib after 48H, the expression of PTEN was increased. Enough to improve the drug resistance of the Erlotinib resistant cell line PC-9/ER; 2.SAHA can promote the apoptosis of PC-9/ER cells; the deletion of 3.PTEN plays a role in the production of Erlotinib resistance; 4.SAHA can improve the expression of PTEN, promote apoptosis, and improve the resistance of Erlotinib.
【學(xué)位授予單位】：安徽醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R734.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉磊;趙羲和;李凱;;帕妥珠單抗與厄洛替尼對(duì)荷瘤小鼠的療效研究[J];解剖科學(xué)進(jìn)展;2008年03期

2 羅俊華;李娟;;厄洛替尼治療老年晚期NSCLC的臨床觀察[J];腫瘤防治研究;2009年03期

3 陳光;鞠春梅;許淼;;厄洛替尼治療老年晚期NSCLC 36例臨床評(píng)價(jià)[J];中國(guó)老年學(xué)雜志;2009年12期

4 ;藥品警戒信息[J];中國(guó)藥物警戒;2009年09期

5 潘小平;蔡光先;劉柏炎;曾柏榮;張紅;;厄洛替尼致病態(tài)竇房結(jié)綜合征[J];藥物不良反應(yīng)雜志;2009年04期

6 白皓;韓寶惠;;厄洛替尼治療非小細(xì)胞肺癌腦轉(zhuǎn)移初步分析[J];中國(guó)肺癌雜志;2009年12期

7 李華榮;孫W毞，

本文編號(hào)：2041380